PL2233150T3 - Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek - Google Patents

Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek

Info

Publication number: PL2233150T3
Authority: PL; Poland
Prior art keywords: epo; liver; cells; treatment; tissue
Prior art date: 2003-12-30

Application number

PL10005293T

Other languages

English (en)

Inventor

Augustinus Bader

Original Assignee

Bader

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-30

Filing date

2004-12-30

Publication date

2017-06-30

2003-12-30 Priority claimed from DE10361813A external-priority patent/DE10361813A1/de

2003-12-30 Priority claimed from EP03029961A external-priority patent/EP1550715A1/de

2004-12-30 Application filed by Bader filed Critical Bader

2017-06-30 Publication of PL2233150T3 publication Critical patent/PL2233150T3/pl

Links

102000003951 Erythropoietin Human genes 0.000 title abstract 6
108090000394 Erythropoietin Proteins 0.000 title abstract 6
229940105423 erythropoietin Drugs 0.000 title abstract 6
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 6
206010052428 Wound Diseases 0.000 title 1
208000027418 Wounds and injury Diseases 0.000 title 1
238000002054 transplantation Methods 0.000 title 1
210000004185 liver Anatomy 0.000 abstract 3
102000036693 Thrombopoietin Human genes 0.000 abstract 2
108010041111 Thrombopoietin Proteins 0.000 abstract 2
108010080379 Fibrin Tissue Adhesive Proteins 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
241000282887 Suidae Species 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000003394 haemopoietic effect Effects 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Otolaryngology (AREA)
Botany (AREA)
Heart & Thoracic Surgery (AREA)

PL10005293T 2003-12-30 2004-12-30 Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek PL2233150T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10361813A DE10361813A1 (de)	2003-12-30	2003-12-30	Verfahren zur Regeneration von Gewebe
EP03029961A EP1550715A1 (de)	2003-12-30	2003-12-30	Verfahren zur Regenation von Gewebe
EP10005293.5A EP2233150B1 (de)	2003-12-30	2004-12-30	Erythropoietin zur Anwendung bei der Behandlung von Wunden oder der Transplantation von Zellen

Publications (1)

Publication Number	Publication Date
PL2233150T3 true PL2233150T3 (pl)	2017-06-30

Family

ID=34740522

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04804424T PL1699915T3 (pl)	2003-12-30	2004-12-30	Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej
PL10005293T PL2233150T3 (pl)	2003-12-30	2004-12-30	Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04804424T PL1699915T3 (pl)	2003-12-30	2004-12-30	Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej

Country Status (14)

Country	Link
US (2)	US7910547B2 (pl)
EP (2)	EP1699915B1 (pl)
JP (2)	JP4903580B2 (pl)
AT (1)	ATE469654T1 (pl)
AU (2)	AU2004309083B2 (pl)
BR (1)	BRPI0418326A (pl)
CA (1)	CA2550301A1 (pl)
DE (1)	DE502004011252D1 (pl)
DK (2)	DK1699915T3 (pl)
ES (2)	ES2346226T3 (pl)
PL (2)	PL1699915T3 (pl)
PT (1)	PT1699915E (pl)
RU (2)	RU2542391C2 (pl)
WO (1)	WO2005063965A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10026480A1 (de) *	2000-05-29	2001-12-13	Augustinus Bader	Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
RU2542391C2 (ru)	2003-12-30	2015-02-20	Аугустинус БАДЕР	Способ регенерации ткани
JP4982841B2 (ja) *	2005-10-12	2012-07-25	国立大学法人名古屋大学	再生医療骨組成物
US20080107632A1 (en) *	2006-09-06	2008-05-08	Henrich Cheng	Fibrin glue composition for repairing nerve damage and methods thereof
JP4696247B2 (ja) *	2006-12-11	2011-06-08	国立大学法人筑波大学	肝線維化抑制剤
JP5098018B2 (ja) *	2007-03-06	2012-12-12	国立大学法人筑波大学	肝炎治療剤
AR065613A1 (es) *	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
EP2018835B1 (de)	2007-07-09	2014-03-05	Augustinus Bader	Wirkstoff abgebendes Pflaster
JP5869219B2 (ja)	2007-08-16	2016-02-24	レメドーバイオメッドリミテッド	治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
EP2222327B1 (de) *	2007-12-28	2017-02-15	Augustinus Bader	Topische anwendung und formulierung von erythropoietin für die wundheilung der haut
JP2011509156A (ja)	2008-01-08	2011-03-24	イェールユニバーシティ	血管移植片の開存性を促進するための組成物および方法
WO2009093240A2 (en) *	2008-01-24	2009-07-30	Ademex Ltd.	Erythropoietin and fibronectin compositions for bone regeneration
EP2257163A4 (en) *	2008-03-10	2012-01-18	Marfly 2 Lp	BONE PASTE COMPOSITION
CN101980714A (zh) *	2008-03-31	2011-02-23	奥古斯蒂努斯·巴德	借助干细胞或骨髓细胞进行组织再生的方法和组合物
AU2009331840B2 (en) *	2008-12-24	2015-03-12	Augustinus Bader	Rapid preparation and use of engineered tissue and scaffolds as individual implants
US20100272816A1 (en) *	2009-04-27	2010-10-28	Wolfgang Rudinger	Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
EP2538875A4 (en) *	2010-02-22	2013-08-21	Harvard College	METHOD OF GENERATING MANIPULATED INNOVATED TISSUE AND USES THEREOF
JP5823986B2 (ja) *	2010-02-23	2015-11-25	セバナメディカルリミテッド	脂肪移植物の生存を増大させるための方法及び組成物
WO2011153512A2 (en)	2010-06-03	2011-12-08	Indiana University Research And Technology Corporation	Use of compounds with thrombopoietic activity to promote bone growth and healing
DK2590666T3 (en)	2010-07-06	2017-07-17	Augustinus Bader	TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
WO2012031778A1 (de)	2010-09-12	2012-03-15	Augustinus Bader	Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
WO2012148200A2 (ko) *	2011-04-26	2012-11-01	아주대학교 산학협력단	허혈성 혈관 질환 치료시술 보조용 조성물
US9993505B2 (en) *	2012-01-31	2018-06-12	Wake Forest University Health Sciences	Innervation of engineered structures
US11311367B2 (en)	2012-01-31	2022-04-26	Wake Forest University Health Sciences	Tissue-engineered gut-sphincter complexes and methods of making the same
US9795965B2 (en)	2013-01-03	2017-10-24	Brigham And Women's Hospital, Inc.	System and method for a biomimetic fluid processing
RU2522816C1 (ru) *	2013-02-12	2014-07-20	Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России)	Композиция для клеточно-заместительной терапии дефектов мягких тканей
EP3126484B1 (en)	2014-03-31	2020-09-23	Brigham and Women's Hospital, Inc.	Systems and methods for biomimetic fluid processing
JP2016067312A (ja) *	2014-09-30	2016-05-09	株式会社ジーシー	軟骨分化培養液、及び軟骨組織
RU2582948C1 (ru) *	2014-10-23	2016-04-27	Ренат Рашитович Ахмеров	Способ волюмизации мягких тканей с помощью термически обработанной тромбоцитарной аутологичной плазмы
US10232048B1 (en) *	2014-11-18	2019-03-19	Divine Api-Logics, LLC	Apitherapy method and composition
EP3359200B1 (en)	2015-10-05	2023-08-02	Board of Regents, The University of Texas System	Micro-and nano-device for cartilage injury detection and treatment
EP3741397B1 (en)	2015-12-11	2025-05-21	Research Institute at Nationwide Children's Hospital	Systems and methods for optimized patient specific tissue engineering vascular grafts
WO2017104725A1 (ja) *	2015-12-16	2017-06-22	第一三共株式会社	創傷治療剤
US20190015190A1 (en)	2015-12-30	2019-01-17	Wake Forest University Health Sciences	Tissue-engineered gut-sphincter complexes and methods of making the same
RU2638796C1 (ru) *	2016-08-05	2017-12-15	Общество с ограниченной ответственностью "Покровский банк стволовых клеток"	Способ получения двухкомпонентного препарата для лечения повреждения суставов путем малоинвазивного введения в суставную сумку и препарат, полученный этим способом
AU2017357374B2 (en)	2016-11-10	2023-05-18	Asc Regenity Ltd.	Cosmetic formulations for topical applications containing erythropoietin-derived molecules
RU2648869C1 (ru) *	2017-04-03	2018-03-28	Анатолий Владимирович Толстов	Способ лечения локальных ожоговых ран II-III А степени
RU2650214C1 (ru) *	2017-04-04	2018-04-11	федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России)	Способ комбинированной остеопластической хирургии околоносовых пазух с использованием фактора роста
RU2666595C1 (ru) *	2017-09-26	2018-09-11	федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации ФГБОУ ВО КубГМУ Минздрава России	Гидрогель для коррекции посттрепанационного дефекта черепа
JP7406809B2 (ja) *	2018-03-20	2023-12-28	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケイション	活力のある歯髄の再生
US12440604B2 (en)	2018-06-13	2025-10-14	University of Pittsburgh—of the Commonwealth System of Higher Education	Bone regeneration in compromised wounds
AU2019305092A1 (en)	2018-07-19	2021-03-11	Platelet Biogenesis, Inc.	Stacked recirculating bioreactor
US12246108B2 (en) *	2019-10-14	2025-03-11	Board Of Regents, The University Of Texas System	Mussel inspired nanocomposite adhesives for biomedical applications
CN113521049A (zh) *	2021-07-29	2021-10-22	姚雷利	一种妊娠纹脱模修复方法
WO2023168153A1 (en) *	2022-03-03	2023-09-07	Fibrobiologics, Inc.	Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
US20250290076A1 (en) *	2022-04-27	2025-09-18	Kyoto University	Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4954437A (en)	1986-09-15	1990-09-04	Integrated Genetics, Inc.	Cell encoding recombinant human erythropoietin
US5716644A (en) *	1992-06-11	1998-02-10	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
US6008047A (en)	1993-04-08	1999-12-28	Livercell L.L.C.	Cell culturing method and medium
CN1057534C (zh)	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
ATE354377T1 (de) *	1993-12-02	2007-03-15	Max Delbrueck Centrum	Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel
WO1995021919A2 (en)	1994-02-14	1995-08-17	Kirin Brewery Company, Limited	Protein having tpo activity
AU691828B2 (en)	1994-02-14	1998-05-28	University Of Washington	Hematopoietic protein and materials and methods for making it
US5766581A (en)	1994-03-31	1998-06-16	Amgen Inc.	Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US7008634B2 (en) *	1995-03-03	2006-03-07	Massachusetts Institute Of Technology	Cell growth substrates with tethered cell growth effector molecules
US5879673A (en)	1996-01-25	1999-03-09	Genentech, Inc.	Administration of thrombopoietin on a single day only
US5817343A (en) *	1996-05-14	1998-10-06	Alkermes, Inc.	Method for fabricating polymer-based controlled-release devices
RU2144815C1 (ru) *	1996-12-24	2000-01-27	Общество с ограниченной ответственностью Научно-производственный центр "Сибирская природная косметика"	Способ получения регенерирующего косметического крема для ухода за кожей
JP2002507907A (ja)	1997-06-27	2002-03-12	バーダー、アウグスチヌス	生合成移植片及びその製造方法
US6165783A (en) *	1997-10-24	2000-12-26	Neuro Spheres Holdings Ltd.	Erythropoietin-mediated neurogenesis
US6776984B1 (en) *	1999-08-20	2004-08-17	George R. Schwartz	Induced regeneration and repair of damaged neurons and nerve axon myelin
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
AU6092900A (en) *	1999-07-14	2001-02-05	Board Of Trustees Of The Leland Stanford Junior University	Animals comprising human hepatocellular tissue
US6555374B1 (en) *	1999-08-19	2003-04-29	Artecel Sciences, Inc.	Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6479064B1 (en) *	1999-12-29	2002-11-12	Children's Medical Center Corporation	Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
DE10034583A1 (de)	2000-07-14	2002-01-31	Axel Haverich	Individuelle Venenklappenprothese
US20040082765A1 (en) *	2000-10-16	2004-04-29	Teruo Nakamura	Peg-modified erythropoietin
EP1345628B1 (en)	2000-12-20	2011-04-13	F. Hoffmann-La Roche AG	Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
US7767643B2 (en) *	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CA2447116A1 (en) *	2001-05-17	2002-11-21	Board Of Trustees Of The University Of Illinois	Methods for treating liver disease and liver damage with growth hormone and foxm1b
US7524513B2 (en) *	2001-06-15	2009-04-28	Mao Hai-Quan	Biofunctional fibers
DE60239217D1 (de) *	2001-11-16	2011-03-31	Childrens Medical Center	Erzeugung gewebetechnologisch hergestellter weiblicher fortpflanzungsorgane
EP1517988B1 (de) *	2002-06-20	2013-05-08	Augustinus Bader	Verwendung von Erythropoietin zur Geweberegeneration in vivo
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
PL396711A1 (pl) *	2002-12-26	2011-12-19	Mountain View Pharmaceuticals, Inc.	Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
DE10303584A1 (de) *	2003-01-30	2004-08-12	Stauss, Robert, Dr.	Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
RU2542391C2 (ru) *	2003-12-30	2015-02-20	Аугустинус БАДЕР	Способ регенерации ткани

2004
- 2004-12-30 RU RU2010105646/10A patent/RU2542391C2/ru active
- 2004-12-30 PL PL04804424T patent/PL1699915T3/pl unknown
- 2004-12-30 JP JP2006546111A patent/JP4903580B2/ja not_active Expired - Lifetime
- 2004-12-30 EP EP04804424A patent/EP1699915B1/de not_active Expired - Lifetime
- 2004-12-30 EP EP10005293.5A patent/EP2233150B1/de not_active Expired - Lifetime
- 2004-12-30 PL PL10005293T patent/PL2233150T3/pl unknown
- 2004-12-30 ES ES04804424T patent/ES2346226T3/es not_active Expired - Lifetime
- 2004-12-30 BR BRPI0418326-6A patent/BRPI0418326A/pt not_active IP Right Cessation
- 2004-12-30 CA CA002550301A patent/CA2550301A1/en not_active Abandoned
- 2004-12-30 RU RU2006120458/13A patent/RU2392314C2/ru active
- 2004-12-30 WO PCT/EP2004/014839 patent/WO2005063965A1/de not_active Ceased
- 2004-12-30 AU AU2004309083A patent/AU2004309083B2/en not_active Expired
- 2004-12-30 ES ES10005293.5T patent/ES2606068T3/es not_active Expired - Lifetime
- 2004-12-30 PT PT04804424T patent/PT1699915E/pt unknown
- 2004-12-30 DE DE502004011252T patent/DE502004011252D1/de not_active Expired - Lifetime
- 2004-12-30 US US10/583,879 patent/US7910547B2/en not_active Expired - Lifetime
- 2004-12-30 DK DK04804424.2T patent/DK1699915T3/da active
- 2004-12-30 AT AT04804424T patent/ATE469654T1/de active
- 2004-12-30 DK DK10005293.5T patent/DK2233150T3/en active
2011
- 2011-02-09 AU AU2011200538A patent/AU2011200538B2/en not_active Expired
- 2011-03-21 US US13/052,800 patent/US20110172150A1/en not_active Abandoned
- 2011-11-10 JP JP2011246261A patent/JP2012067117A/ja active Pending

Also Published As

Publication number	Publication date
PT1699915E (pt)	2010-08-31
EP2233150A2 (de)	2010-09-29
AU2004309083B2 (en)	2010-11-11
EP1699915B1 (de)	2010-06-02
DE502004011252D1 (de)	2010-07-15
AU2011200538B2 (en)	2012-02-23
US20110172150A1 (en)	2011-07-14
EP1699915A1 (de)	2006-09-13
JP2007517001A (ja)	2007-06-28
RU2010105646A (ru)	2011-08-27
DK1699915T3 (da)	2010-09-13
EP2233150A3 (de)	2013-01-09
ES2346226T3 (es)	2010-10-13
JP2012067117A (ja)	2012-04-05
US20080031850A1 (en)	2008-02-07
JP4903580B2 (ja)	2012-03-28
BRPI0418326A (pt)	2007-05-02
RU2392314C2 (ru)	2010-06-20
ATE469654T1 (de)	2010-06-15
PL1699915T3 (pl)	2010-11-30
US7910547B2 (en)	2011-03-22
ES2606068T3 (es)	2017-03-17
DK2233150T3 (en)	2016-12-12
EP2233150B1 (de)	2016-09-07
AU2004309083A1 (en)	2005-07-14
AU2011200538A1 (en)	2011-03-03
WO2005063965A1 (de)	2005-07-14
RU2006120458A (ru)	2008-02-10
CA2550301A1 (en)	2005-07-14
RU2542391C2 (ru)	2015-02-20

Publication	Publication Date	Title
PL2233150T3 (pl)	2017-06-30	Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
ES2351875T3 (es)	2011-02-11	Utilización de inhibidores de las lisil oxidasas para el cultivo celular y la ingeniería tisular.
Navsaria et al.	1995	Culturing skin in vitro for wound therapy
ATE188383T1 (de)	2000-01-15	Mischungen zum schutz und regenierung von geweben
US20150258145A1 (en)	2015-09-17	Tissue transplant compositions and methods for use
CA2323073A1 (en)	1999-09-16	Uses for human non-autologous mesenchymal stem cells
JPS59192364A (ja)	1984-10-31	軟骨および骨の修復方法
CA2387542A1 (en)	2001-05-10	Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU8476698A (en)	1999-01-25	Human mesenchymal stem cells from peripheral blood
KR20130009651A (ko)	2013-01-23	콜라겐, 히알루론산 유도체 및 포유류의 탯줄 유래 줄기세포를 포함하는 연골세포치료제
JP2006510399A (ja)	2006-03-30	未分化間葉細胞を用いた組織の治療
EP1077254A3 (en)	2002-02-06	Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
Wilkes et al.	1985	The long-term survival of onlay bone grafts—a comparative study in mature and immature animals
NO924323L (no)	1993-05-12	Nye hybridtransformerende vekstfaktorer
DE69009748D1 (de)	1994-07-14	Fgf enthaltende stabilisierte zubereitungen.
PT941329E (pt)	2004-11-30	Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
EP1405906A4 (en)	2008-03-19	SCHWANN CELLS FROM INTERSTITIAL MYELOID CELLS
IL144523A0 (en)	2002-05-23	Method and compositions for healing and repair of articular cartilage
ATE359798T1 (de)	2007-05-15	Verwendungvon dextransulfat zur behandlung von ibmir
CN102172337B (zh)	2013-10-23	具有皮脂腺样结构的组织工程皮肤及其制备方法
Tan et al.	2015	Low-intensity pulsed ultrasound (LIPUS) and pulsed electromagnetic field (PEMF) treatments affect degeneration of cultured articular cartilage explants
RU2545993C2 (ru)	2015-04-10	Способ восстановления костных дефектов трубчатых костей критической величины
RU2452527C1 (ru)	2012-06-10	Способ регенерации хрящевой гиалиновой ткани суставов на начальных стадиях деструктивных заболеваний
Hemalatha et al.	2017	Dental stem cells origin, banking, engineering and applications
Ulrich	2014	Regenerative medicine in burn wound healing: Aiming for the perfect skin.